


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A method for the prophylaxis and/or treatment of one or more diseases or disorders, selected from autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries, comprising, administering to a subject in need thereof, an effective amount of a compound of formula (I):



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

A is a 5-8 membered heterocyclic or carbocyclic group, wherein said carbocyclic group may be fused with aryl, heteroaryl, cycloalkyl or heterocycloalkyl;

X is S or O ~~S, O or NH~~;

Y<sup>1</sup> and Y<sup>2</sup> are independently S or O ~~S, O or NH~~;



Z is S or O;

R<sup>1</sup> is H, CN, carboxy, acyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, halogen, hydroxy, acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, ammonium, sulfonyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyloxy, sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, sulfonylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylamino or carbamate;

$R^2$  is selected from the group consisting of H, halogen, acyl, amino,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_1$ - $C_6$ -alkyl carboxy,  $C_1$ - $C_6$ -alkyl acyl,  $C_1$ - $C_6$ -alkyl alkoxycarbonyl,  $C_1$ - $C_6$ -alkyl aminocarbonyl,  $C_1$ - $C_6$ -alkyl acyloxy,  $C_1$ - $C_6$ -alkyl acylamino,  $C_1$ - $C_6$ -alkyl ureido,  $C_1$ - $C_6$ -alkyl amino,  $C_1$ - $C_6$ -alkyl alkoxy,  $C_1$ - $C_6$ -alkyl sulfanyl,  $C_1$ - $C_6$ -alkyl sulfinyl,  $C_1$ - $C_6$ -alkyl sulfonyl,  $C_1$ - $C_6$ -alkyl sulfonylaminoaryl, aryl,  $C_3$ - $C_8$ -cycloalkyl or heterocycloalkyl,  $C_1$ - $C_6$ -alkyl aryl,  $C_2$ - $C_6$ -alkenyl-aryl,  $C_2$ - $C_6$ -alkynyl aryl, carboxy, cyano, hydroxy,  $C_1$ - $C_6$ -alkoxy, nitro, acylamino, ureido,  $C_1$ - $C_6$ -alkyl carbamate, sulfonylamino, sulfanyl, or sulfonyl;

n is 0, 1 or 2;

with the proviso that the following compounds are excluded:



wherein  $R^1$  is a lower alkyl or aralkyl and  $R^2$  is H or a halogen.

Claim 2 (Previously Presented): The method according to claim 1, wherein said one or more diseases are selected from the group consisting of multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, lung inflammation, and thrombosis or brain infection/inflammation such as meningitis or encephalitis.

Claim 3 (Previously Presented): The method according to claim 1, wherein said one or more diseases are selected from the group consisting of Alzheimer's disease, Huntington's disease, CNS trauma, stroke and ischemic conditions.

Claim 4 (Previously Presented): The method according to claim 1, wherein said one or more diseases are selected from the group consisting of atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure and vasoconstriction.


Claim 5 (Previously Presented): The method according to claim 1, wherein said one or more diseases or disorders are selected from the group consisting of chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke or ischemic conditions, ischemia reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, pancreatitis, multiorgane failure, angiogenesis, invasion metastasis, melanoma, Karposi's sarcoma, acute and chronic bacterial and viral infections, sepsis, transplantation graft rejection, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung and general lung airways inflammation.

Claim 6 (Previously Presented): The method according to claim 1, wherein  $Y^1$  and  $Y^2$  are both oxygen.

Claim 7 (Previously Presented): The method according to claim 1, wherein n is 1 or 2 and  $R^1$  and  $R^2$  are both H.

Claim 8 (Previously Presented): The method according to claim 1, wherein, in the compound of formula (I), X is S, Y<sup>1</sup> and Y<sup>2</sup> are both O, and n is 0.

Claim 9 (Currently Amended): The method according to claim 1, whereby the compound of formula (I) is a thiazolidinone-vinyl fused-benzene derivative of the formula (Ia)




wherein Y<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup>, Z and n are as above defined for the compound of formula (I);  
V and W are each, independently from each other, O, S or -NR<sup>3</sup> wherein R<sup>3</sup> is H or C<sub>1</sub>-C<sub>6</sub> alkyl;

G is a C<sub>1</sub>-C<sub>5</sub> alkylene or a C<sub>1</sub>-C<sub>5</sub> alkenylene group;

o and m are each, independently from each other, 0 or 1; and


q is an integer from 0 to 4.

Claim 10 (Currently Amended): The method according to claim 9, whereby the thiazolidinone-vinyl fused-benzene derivative has the formula (Ib):




wherein  $Y^1$ ,  $R^1$ ,  $R^2$ ,  $V$ ,  $Z$ ,  $W$ ,  $m$ ,  $n$ ,  $o$ ,  $q$  are as above defined in the compound of formula (Ia), and  $p$  is an integer from 1 to 4.

Claim 11 (Currently Amended): The method according to claim 9, whereby the thiazolidinone-vinyl fused-benzene derivative has the formula (Ic):



wherein  $W$ , as well as  $R^1$  and  $Y^1$ , are as above defined in the compound of formula (Ia).

Claim 12 (Currently Amended): The method according to claim 9, whereby the thiazolidinone-vinyl fused-benzene derivative has the formula (Id):



wherein  $R^1$ ,  $R^2$ ,  $Z$  and  $n$  are as above defined in formula (Ia);  $o$  is 0 or 1;  
 $p$  is an integer from 1 to 4 and  $q$  is an integer from 0 to 4.


Claim 13 (Previously Presented): The method according to claim 9, wherein, in formula (Ia), Z is O, m is 0, n is 1, p is 1 or 2, q is 1, and  $R^1$  and  $R^2$  are each as above defined for the compound of formula (Ia).

Claim 14 (Previously Presented): The method according to claim 9, wherein, in formula (Ia), m is 1, n is 0, p is 1 or 2, q is 0, and  $R^1$  and  $R^2$  are each as above defined for the compound of formula (Ia).

Claim 15 (Previously Presented): The method according to claim 9, wherein, in formula (Ia), m is 0, n is 1, p is 1 or 2, q is 0, and  $R^1$  and  $R^2$  are each as defined above for the compound of formula (I).

Claim 16 (Previously Presented): The method according to claim 9, wherein, in formula (Ia),  $R^1$  is halogen or hydrogen.

Claim 17 (Currently Amended): A method for the prophylaxis and/or treatment of one or more diseases mediated by PI3 kinase, comprising administering to a subject in need thereof, an effective amount of a compound of formula (I):



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

A is a 5-8 membered heterocyclic or carbocyclic group, wherein said carbocyclic group may be fused with aryl, heteroaryl, cycloalkyl or heterocycloalkyl;

X is S or O, ~~S, O or NH~~;

Y<sup>1</sup> and Y<sup>2</sup> are independently S or O, ~~S, O or NH~~;



Z is S or O;

R<sup>1</sup> is H, CN, carboxy, acyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, halogen, hydroxy, acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, ammonium, sulfonyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyloxy, sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, sulfonylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylamino or carbamate;

R<sup>2</sup> is selected from the group consisting of H, halogen, acyl, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylaminoaryl, aryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, carboxy, cyano, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, nitro, acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl carbamate, sulfonylamino, sulfanyl, and sulfonyl;

n is 0, 1 or 2;


with the proviso that the following compounds are excluded



wherein R<sup>1</sup> is a lower alkyl or aralkyl and R<sup>2</sup> is H or a halogen.

Claim 18 (Previously Presented): The method according to claim 17, wherein said PI3 kinase is a PI3 kinase  $\gamma$ .

Claim 19 (Currently Amended): A thiazolidinone-vinyl fused-benzene derivative according to formula (II-a):




wherein A is selected from the group consisting of dioxol, dioxin, dihydrofuran, (dihydro) furanyl, (dihydro)oxaziny, pyridinyl, isooxazolyl, oxazolyl (dihydro)naphthalenyl, pyrimidinyl, triazolyl, imidazolyl, pyrazinyl, thiazolidinyl, thiadiazolyl, and oxadiazolyl;

R<sup>2</sup> is selected from the group consisting of H, halogen, acyl, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino,



C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl carbamate, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylaminoaryl, aryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, carboxy, cyano, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, and sulfonyl.

Claim 20 (Currently Amended): A thiazolidinone-vinyl fused-benzene derivative according to formula (II):



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

$Y^1$  is S or O S, ~~O or NH~~;

Z is S or O;

R<sup>1</sup> is H, CN, carboxy, acyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, halogen, hydroxy, acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, ammonium, sulfonyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyloxy, sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, sulfonylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylamino or carbamate;

R<sup>2</sup> is selected from the group consisting of H, halogen, acyl, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl


alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylaminoaryl, aryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, carboxy, cyano, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, nitro, acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl carbamate, sulfonylamino, sulfanyl, and sulfonyl;

n is 0 or 1.

Claim 21 (Currently Amended): The thiazolidinone-vinyl fused-benzene derivative according to claim 20, wherein Y<sup>1</sup> is O.

Claim 22 (Currently Amended): The thiazolidinone-vinyl fused-benzene derivative according to claim 20, wherein R<sup>1</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, aryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl and C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl.

Claim 23 (Currently Amended): A thiazolidinone-vinyl fused-benzene derivative according to formula (III):




as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, and wherein

$R^1$  is H, CN, carboxy, acyl,  $C_1$ - $C_6$ -alkoxy, halogen, hydroxy, acyloxy,  $C_1$ - $C_6$ -alkyl carboxy,  $C_1$ - $C_6$ -alkyl acyloxy,  $C_1$ - $C_6$ -alkyl alkoxy, alkoxycarbonyl,  $C_1$ - $C_6$ -alkyl alkoxycarbonyl, aminocarbonyl,  $C_1$ - $C_6$ -alkyl aminocarbonyl, acylamino,  $C_1$ - $C_6$ -alkyl acylamino, ureido,  $C_1$ - $C_6$ -alkyl ureido, amino,  $C_1$ - $C_6$ -alkyl amino, ammonium, sulfonyloxy,  $C_1$ - $C_6$ -alkyl sulfonyloxy, sulfonyl,  $C_1$ - $C_6$ -alkyl sulfonyl, sulfinyl,  $C_1$ - $C_6$ -alkyl sulfinyl, sulfanyl,  $C_1$ - $C_6$ -alkyl sulfanyl, sulfonylamino,  $C_1$ - $C_6$ -alkyl sulfonylamino or carbamate;

$R^2$  is selected from the group consisting of H, halogen, acyl, amino,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_1$ - $C_6$ -alkyl carboxy,  $C_1$ - $C_6$ -alkyl acyl,  $C_1$ - $C_6$ -alkyl alkoxycarbonyl,  $C_1$ - $C_6$ -alkyl aminocarbonyl,  $C_1$ - $C_6$ -alkyl acyloxy,  $C_1$ - $C_6$ -alkyl acylamino,  $C_1$ - $C_6$ -alkyl ureido,  $C_1$ - $C_6$ -alkyl amino,  $C_1$ - $C_6$ -alkyl alkoxy,  $C_1$ - $C_6$ -alkyl sulfanyl,  $C_1$ - $C_6$ -alkyl sulfinyl,  $C_1$ - $C_6$ -alkyl sulfonyl,  $C_1$ - $C_6$ -alkyl sulfonylaminoaryl, aryl,  $C_3$ - $C_8$ -cycloalkyl or heterocycloalkyl,  $C_1$ - $C_6$ -alkyl aryl,  $C_2$ - $C_6$ -alkenyl-aryl,  $C_2$ - $C_6$ -alkynyl aryl, carboxy, cyano, hydroxy,  $C_1$ - $C_6$ -alkoxy, nitro, acylamino, ureido,  $C_1$ - $C_6$ -alkyl carbamate, sulfonylamino, sulfanyl, and sulfonyl.

Claim 24 (Currently Amended): A thiazolidinone-vinyl fused-benzene derivative according any of formulae (IV), (V) and (VI):



wherein R<sup>1</sup> is selected from the group consisting of hydrogen, halogen, cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, acyl, and alkoxy carbonyl, and

R<sup>2</sup> is selected from the group consisting of H, halogen, acyl, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylaminoaryl, aryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, carboxy, cyano, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, nitro, acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl carbamate, sulfonylamino, sulfanyl, and sulfonyl.

Claim 25 (Currently Amended): The thiazolidinone-vinyl fused-benzene derivative according to claim 19, selected from the group consisting of:

- 5-(1,3-benzodioxol-5-ylmethylene)-1,3-thiazolidine-2,4-dione,
- 5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo-1,3-thiazolidin-4-one,
- 5-(2,3-dihydro-1,4-benzodioxin-6-ylmethylene)-1,3-thiazolidine-2,4-dione,
- 5-(2,3-dihydro-1-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione,
- 5-[(7-methoxy-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione,

5-[(9,10-dioxo-9,10-dihydroanthracen-2-yl)methylene]-1,3-thiazolidine-2,4-dione,  
5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione,  
(5Z)-5-(1,3-dihydro-2-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione,  
5-(1-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione,  
5-[(4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]-1,3-thiazolidine-  
2,4-dione,  
5-(1,3-benzodioxol-5-ylmethylene)-2-imino-1,3-thiazolidin-4-one,  
5-Quinolin-6-ylmethylene-thiazolidine-2,4-dione,  
5-Quinolin-6-ylmethylene-2-thioxo-thiazolidin-4-one,  
2-Imino-5-quinolin-6-ylmethylene-thiazolidin-4-one,  
5-(3-Methyl-benzo[d]isoxazol-5-ylmethylene)-thiazolidine-2,4-dione,  
5-(4-Phenyl-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione,  
5-(4-Dimethylamino-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione,  
5-[(4-aminoquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione,  
5-[(4-piperidin-1-ylquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione,  
5-[(4-morpholin-4-ylquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione,  
5-{[4-(benzylamino)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,  
5-{[4-(diethylamino)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,  
5-({4-[(pyridin-2-ylmethyl)amino]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-  
dione,  
5-({4-[(pyridin-3-ylmethyl)amino]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-  
dione,  
ethyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}piperidine-3-  
carboxylate,

ethyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}piperidine-4-carboxylate,

tert-butyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}-L-prolinate,

5-{ [4-(4-methylpiperazin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-{[4-(4-pyrimidin-2-ylpiperazin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-({4-[4-(4-fluorophenyl)piperidin-1-yl]quinazolin-6-yl }methylene)-1,3-thiazolidine-2,4-dione,

5-{ [4-(4-benzylpiperidin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-({4-[4-(2-phenylethyl)piperidin-1-yl]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-{ [4-(4-methylpiperidin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-{ [4-(4-hydroxypiperidin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-piperidine-4-carboxylic acid,

1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-piperidine-3-carboxylic acid,

1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-pyrrolidine-2-carboxylic acid,

5-(4-Methylamino-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione,

5-(4-Methoxy-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione

2-Imino-5-(4-methylamino-quinazolin-6-ylmethylene)-thiazolidin-4-one,

2-Imino-5-(4-piperidine-quinazolin-6-ylmethylene)-thiazolidin-4-one,  
2-Imino-5-(4-dimethylamino-quinazolin-6-ylmethylene)-thiazolidin-4-one,  
5-(2-Methyl-2H-benzotriazol-5-ylmethylene)-thiazolidine-2,4-dione,  
5-(3-Methyl-3H-benzotriazol-5-ylmethylene)-thiazolidine-2,4-dione,  
5-(3-Ethyl-3H-benzoimidazol-5-ylmethylene)-thiazolidine-2,4-dione,  
5-([1-(4-phenylbutyl)-1H-benzimidazol-6-yl]methylene)-1,3-thiazolidine-2,4-dione,  
5-[(1-prop-2-yn-1-yl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione,  
5-[(1-{2-[4-(trifluoromethyl)phenyl] ethyl} -1H-benzimidazol-6-yl)methylene]-1,3-  
thiazolidine-2,4-dione,  
5-([1-[2-(4-hydroxyphenyl)ethyl]-1H-benzimidazol-6-yl]methylene)-1,3-  
thiazolidine-2,4-dione,  
methyl 4-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1H-benzimidazol-1-  
yl}cyclohexanecarboxylate,  
5-([1-[2-(5-methoxy-1H-indol-3-yl)ethyl]-1H-benzimidazol-6-yl]methylene)-1,3-  
thiazolidine-2,4-dione,  
5-([1-[(1-methyl-1H-pyrazol-4-yl)methyl]-1H-benzimidazol-6-yl]methylene)-1,3-  
thiazolidine-2,4-dione,  
5-([1-[2-(3,4-dimethoxyphenyl)ethyl]-1H-benzimidazol-6-yl]methylene)-1,3-  
thiazolidine-2,4-dione,  
5-([1-[2-(4-phenoxyphenyl)ethyl]-1H-benzimidazol-6-yl]methylene)-1,3-  
thiazolidine-2,4-dione,  
5-([1-[4-(trifluoromethyl)benzyl]-1H-benzimidazol-6-yl]methylene)-1,3-  
thiazolidine-2,4-dione,  
4-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1H-benzimidazol-1-  
yl}cyclohexanecarboxylic acid,

5-[(1-isobutyl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione,  
5-({1-[2-(1,3-benzodioxol-4-yl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione,  
5-({1-[2-(2-phenoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione,  
5-1[1-(3,3-diphenylpropyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione,  
5-{[1-(2-methoxybenzyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione,  
5-{[1-(3-furylmethyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione,  
5-[(1-propyl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione,  
5-Quinoxalin-6-ylmethylene-thiazolidine-2,4-dione,  
5-Quinoxalin-6-ylmethylene-2-thioxo-thiazolidin-4-one,  
2-Imino-5-quinoxalin-6-ylmethylene-thiazolidin-4-one,  
5-Benzothiazol-6-ylmethylene-thiazolidine-2,4-dione,  
5-(3-Methyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,  
5-(2-Bromo-3-methyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,  
5-(3-bromo-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,  
3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-acrylic acid ethyl ester,  
3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-acrylic acid,  
5-[3-(3-Oxo-3-piperidin-1-yl-propenyl)-benzofuran-5-ylmethylene]-thiazolidine-2,4-dione,  
Methyl 1-((3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)prolinate,



Methyl 1-((3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)-D-prolinate,

(5-({3-[(3-oxo-3-pyrrolidin-1-ylprop-1-en-1-yl)-1-benzofuran-5-yl]methylene)-1,3-thiazolidine-2,4-dione,

5-({3-[3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

Methyl 1-(3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)-L-prolinate,

N-cyclohexyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-methylacrylamide,

3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-ethyl-N-(2-hydroxyethyl)acrylamide,

N-cyclobutyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide,

5-({3-[3-azetidin-1-yl-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({3-[3-(1,3-dihydro-2H-isoindol-2-yl)-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({3-[3-azepan-1-yl-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-piperidin-1-ylacrylamide,

3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-(pyridin-3-ylmethyl)acrylamide,

N-cyclohexyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}  
acrylamide,

5-({3-[3-(4-methylpiperazin-1-yl)-3-oxoprop-1-en-1-yl]-1-benzofuran-5-  
yl}methylene)-1,3-thiazolidine-2,4-dione,

N-cycloheptyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-  
yl}acrylamide,

5-({3-[3-(2,5-dihydro-1H-pyrrol-1-yl)-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}  
methylene)-1,3-thiazolidine-2,4-dione,

N-cyclopentyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-  
yl}acrylamide,

3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-propionic acid ethyl  
ester,

3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-propionic acid,

5-[3-(3-Oxo-3-piperidin-1-yl-propyl)-benzofuran-5-ylmethylene]-thiazolidine-2,4-  
dione,

6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2,3-dihydro-benzo[1,4]oxazine-4-  
carboxylic acid tert-butyl ester,

5-(3,4-Dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,

5-(4-Benzoyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-  
dione,

5-(4-Acetyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,

6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzo[1,4]oxazine-4-carboxylic acid tert-  
butyl ester,

[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-benzo[1,4]-oxazin-4-  
yl]-acetic acid methyl ester,

N-Benzyl-2-[6-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl]-acetamide,  
5-(4-Butyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,  
5-(4-Benzyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,  
5-(2-Chloro-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,  
5-(3-Amino-benzo[d]isoxazol-5-ylmethylene)-thiazolidine-2,4-dione,  
5-(3-Phenylethynyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,  
5-Benzo[1,2,5]thiadiazol-5-ylmethylene-thiazolidine-2,4-dione,  
5-Benzo[1,2,5]oxadiazol-5-ylmethylene-thiazolidine-2,4-dione,  
5-(2-Methyl-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione,  
5-(2-Carboxymethyl-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione,  
5-(3-Bromo-2-fluoro-2,3-dihydro-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione,  
and  
5-(2-Fluoro-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione.

Claim 26 (Currently Amended): A method of preparing a medicament, comprising, contacting the thiazolidinone-vinyl fused-benzene ~~derivative~~ according to claim 19, with one or more pharmaceutically acceptable additives.

Claim 27 (Currently Amended): A pharmaceutical composition, comprising at least one thiazolidinone-vinyl fused-benzene ~~derivative~~ according to claim 19, and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 28 (Currently Amended): A method for the prophylaxis and/or treatment of one or more diseases or disorders, selected from autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries, comprising, administering to a subject in need thereof, an effective amount of the thiazolidinone-vinyl fused-benzene derivative according to claim 19.

Claim 29 (Previously Presented): The method according to claim 28, wherein said one or more diseases are selected from the group consisting of multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, lung inflammation, and thrombosis or brain infection/inflammation such as meningitis or encephalitis.


Claim 30 (Previously Presented): The method according to claim 28, wherein the said one or more diseases are selected from the group consisting of Alzheimer's disease, Huntington's disease, CNS trauma, stroke and ischemic conditions.

Claim 31 (Previously Presented): The method according to claim 28, wherein said one or more diseases are selected from the group consisting of atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure and vasoconstriction.

Claim 32 (Previously Presented): The method according to claim 28, wherein said one or more diseases are selected from the group consisting of chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke or ischemic conditions, ischemia-reperfusion, platelets aggregation/activation, skeletal muscle

atrophy/hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastasis, melanoma, Kaposi's sarcoma, acute and chronic bacterial and viral infections, sepsis, transplantation, graft rejection, pancreatitis, multiorgane failure, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung and general lung airways inflammation.

Claim 33 (Currently Amended): A method for the prophylaxis and/or treatment of one or more diseases mediated by PI3 kinase, comprising administering to a subject in need thereof, an effective amount of a thiazolidinone-vinyl fused-benzene derivative according to formula (II-a):




wherein A is selected from the group consisting of dioxol, dioxin, dihydrofuran, (dihydro) furanyl, (dihydro)oxazinyl, pyridinyl, isooxazolyl, oxazolyl (dihydro)naphthalenyl, pyrimidinyl, triazolyl, imidazolyl, pyrazinyl, thiazolidinyl, thiadiazolyl, and oxadiazolyl;

R<sup>2</sup> is selected from the group consisting of H, halogen, acyl, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl carbamate, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylaminoaryl, aryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, C<sub>2</sub>-C<sub>6</sub>-

alkynyl aryl, carboxy, cyano, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, and sulfonyl.


Claim 34 (Previously Presented): The method according to claim 33, wherein said PI3 Kinase is a PI3 Kinase- $\gamma$ .

Claim 35 (Currently Amended): A method of preparing a thiazolidinone-vinyl fused-benzene derivative of formula (II), according to claim 20, comprising the following step:



wherein R<sup>1</sup>, R<sup>2</sup>, Y<sup>1</sup>, Z and n are as above defined in formula (II).


Claim 36 (Currently Amended): A method of preparing a thiazolidinone-vinyl fused-benzene derivative of formula (III), according to claim 23, comprising the following step:



wherein R<sup>1</sup>, R<sup>2</sup> are as above defined for formula (III), and

Y<sup>1</sup> is O, S or NH.

Claim 37 (Currently Amended): A composition, comprising, a compound according to formula (I):



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

A is a 5-8 membered heterocyclic or carbocyclic group, wherein said carbocyclic group may be fused with aryl, heteroaryl, cycloalkyl or heterocycloalkyl;

X is S or O, ~~S, O or NH~~;

Y<sup>1</sup> and Y<sup>2</sup> are independently S or O, ~~S, O or NH~~;

Z is S or O;



R<sup>1</sup> is H, CN, carboxy, acyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, halogen, hydroxy, acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, ammonium, sulfonyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyloxy, sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, sulfonylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylamino or carbamate;

R<sup>2</sup> is selected from the group consisting of H, halogen, acyl, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino,

C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylaminoaryl, aryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, carboxy, cyano, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, nitro, acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl carbamate, sulfonylamino, sulfanyl, or sulfonyl;

n is 0, 1 or 2;

with the proviso that the following compounds are excluded:



wherein R<sup>1</sup> is a lower alkyl or aralkyl and R<sup>2</sup> is H or a halogen.